The objective is the recruitment of talent with deep learning and biochemistry knowledge in Taiwan

TAIPEI, TAIWAN - Media OutReach- February 25, 2019 - Insilco Medicine, one of the world's leading artificialintelligence (AI) companies in the field of deep learning for drug discovery,will host MolHack 2019 in Taiwan, an online talent competition/hackathon fromFebruary 25th to March 31st.   With afocus of "Deep Learning for Small Molecule Generation," the event is expectedto attract top teams in deep learning and biochemistry from around the world toparticipate. The top prize is a 15" MacBook Pro, with second and third prizesof high-end NVIDIA GPUs.   Additionally,the top 3 entrants in Taiwan will have the opportunity to join InsilicoMedicine as a member of its R&D team.

MolHack 2019: Deep Learning Hackathon for DrugDiscovery

Traditional drugdiscovery efforts take years or even decades to develop new pharmaceuticals.Insilico Medicine aims to dramatically shorten this time by applying deeplearning techniques. The most important aspect of deep learning AI drugdiscovery methods is the ability to design novel molecular structures withspecific characteristics of interest.

During thiscompetition, participants should design and train Generative Deep NeuralNetworks, conditioned on molecular fingerprints, to show the ability togenerate new molecular structures with similar fingerprints.

Insilico Medicinehas been hosting hackathons since its inception, and hackathons are one of thecompany's primary tools for recruiting new talent.  Over the years, the company's hackathons haveattracted numerous young scientists and rising stars from around the world inthe bioscience and information industries. In April 2018, Insilico hosted ahackathon inviting participants to develop algorithms to predict the bindingactivity of ligands to proteins under specific structural conditions. Taiwaneseentrant Cynthia Yang won first place in Taiwan and second place in the world,which led to her recruitment by Insilico Taiwan as part of its R&D staff,where she now works on both local and international projects.  The company provides an excellent workingenvironment, international exposure and ample opportunities for personal growthin this fast-growing field.

We fully expectto see some very exciting outcomes from this event, and we invite talentedyoung scientists in Taiwan and around the world to participate!

To register forthe MolHack 2019 Online Hackathon, please visit this link:
https://molhack.com/

The Rise of Deep Learning

Over the past fewyears, deep learning has become an essential research tool in many differentdomains and industries. The latest advancements have made it possible forneural networks to perform certain tasks better than humans. Deep learningtechniques have also helped us to find solutions to previously impossibleproblems, and this will continue to be a trend well into the future.

With this rise indeep learning, the share of artificial intelligence-related jobs has risen from20% in 2016 to 31.6% in 2017 and continues to grow. It is estimated that thenumber of jobs related to artificial intelligence will reach 2.3 million in2020.

About Insilico Medicine

The expression in silico is an allusion to the commonlyused Latin phrases in biology, in vivo, in vitro and insitu, that refer to experiments done inside living organisms, in the lab,or where they are found in nature, respectively.  Insilico refers to biological experiments that are "performed onsilicon, via computer simulation."

Insilico Medicinepioneered applications of generative adversarial networks (GANs) andreinforcement learning for the generation of novel molecular structures fordiseases with both a known target and with no known targets.  It is a pioneer in the use of deep learning toassist the generation of novel molecular structures with desiredcharacteristics. Insilico Medicine is committed to using deep learningtechniques to help shorten drug development cycle time and cost and toaccelerate the research and development of anti-aging and disease-relateddrugs.

The companycollaborates with pharmaceutical companies worldwide and is pursuing new drugdiscovery programs in cancer, dermatological diseases, fibrosis, Parkinson'sDisease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.

The company's Smart's Pharma.AI divisionis currently a collaborative research and development partner forbiotechnology, pharmaceutical, and skin care manufacturers worldwide, andprovides advanced artificial intelligence learning services to many governmentsand foundations.

Insilico Medicine is located in theEmerging Technology Center of the East Campus of Johns Hopkins University inRockville, MD USA. It has R&D resource centers in Belgium, Russia, Taiwan,Korea, and the United Kingdom.

In 2017, Nvidia named Insilico Medicineas one of the Top 5 AI companies for social impact potential. In 2018, CBInsights listed the company among its global top 100 AI companies. In 2018 itreceived the Frost & Sullivan 2018 North American ArtificialIntelligence for Aging Research and Drug Development Award accompanied byan industry brief.

Brief companyvideo: https://www.youtube.com/watch?v=l62jlwgL3v8.

Website:  https://www.insilico.com

News contact:

Artur Kadurin, CEO of Insilico Taiwan Ltd.

Email:artur@insilico.com

SWEM MarketingConsultant Co., Ltd., Shen An Chueh

TEL:+886-2-23691318#103 Mobile: +886-975-019-217

Email:ann@swem.com.tw